Jove
Visualize
Contact Us

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers.

Cancer chemotherapy and pharmacology·2021
Same author

Prenatal Exposure to Cocaine Impairs Neuronal Coding of Attention and Discriminative Learning<sup>a</sup>.

Annals of the New York Academy of Sciences·2017
Same author

Key considerations in the preclinical development of biosimilars.

Drug discovery today·2015
Same author

The preclinical development of biosimilars: introduction.

Drug discovery today·2015
Same author

Impact of universal disinfectant cap implementation on central line-associated bloodstream infections.

American journal of infection control·2014
Same author

Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars.

Seminars in oncology·2014
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 2, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

Developing clinical trials for biosimilars.

Lynne A Bui1, Carrie Taylor2

  • 1Founder and Chairman, Global Cancer Research Institute, Inc. (GCRI) for Personalized Oncology, San Jose, CA.

Seminars in Oncology
|February 25, 2014
PubMed
Summary
This summary is machine-generated.

Biosimilars offer safe, effective, and affordable treatments by demonstrating high similarity to reference biologics through rigorous clinical trials and pharmacovigilance. These complex biologic drugs require extensive evaluation, not direct duplication, to ensure patient safety and accessibility.

More Related Videos

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

16.9K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

20.2K

Related Experiment Videos

Last Updated: May 2, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

16.9K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

20.2K

Area of Science:

  • Pharmaceutical Sciences
  • Clinical Pharmacology
  • Regulatory Science

Background:

  • Biosimilars present accessible, affordable alternatives to biologics for various diseases, including cancer.
  • Unlike generics, biosimilars are highly similar but not identical to reference biologics due to molecular complexity.

Purpose of the Study:

  • To review critical considerations for biosimilar clinical trials and regulatory evaluation.
  • To discuss the scientific basis for biosimilar approval and post-market surveillance.

Main Methods:

  • Physicochemical characterization and comparability exercises to establish molecular similarity.
  • In vitro, in vivo, and pharmacokinetic/pharmacodynamic (PK/PD) studies.
  • Robust pharmacovigilance strategies for ongoing safety monitoring.

Main Results:

  • Demonstrating high similarity is key, but full characterization may be challenging.
  • Regulatory guidance, clinical trial design, and indication extrapolation are crucial evaluation aspects.
  • European and Canadian experiences offer insights into biosimilar development.

Conclusions:

  • Biosimilars require a comprehensive evaluation framework, including analytical, clinical, and post-marketing data.
  • Ensuring biosimilar safety and efficacy relies on demonstrating similarity and continuous monitoring.
  • Regulatory pathways facilitate the development and approval of biosimilars, enhancing patient access.